After months of extensive information collection and hard work, BIDI Vapor seeks an order to authorize the marketing of the BIDI® Stick.
MELBOURNE, Fla., September 8, 2020—BIDI Vapor has submitted a group of premarket tobacco applications to the U.S. Food and Drug Administration (FDA) for the BIDI® Stick. A grant of these orders would allow these products to stay on the market after September 9, 2020, the FDA’s deadline.
BIDI® Stick, a disposable vape pen, comes in a nicotine concentration of 6% weight/volume. Over 285,000 pages submission bundled the 11 flavor varieties of BIDI® Stick, highlighting its science-based evidence that it is appropriate for protecting public health. The applications include a range of scientific studies, three independent and one “combined” consumer surveys, in-vitro and in-vivo toxicity testing, and HPHC (Harmful and Potentially Harmful Constituents) aerosol and e-liquids tests.
“To get approval to market the BIDI® Stick, we make sure that our PMTA submission was based on science and facts,” said Niraj Patel, the president and CEO of BIDI Vapor. “It is our mission to provide every adult smoker an option to traditional, combustible tobacco that meets their nicotine needs while combating underage use.”
Bidi Vapor implemented age- and identity-verification restrictions to ensure that no underage individuals can access or use the BIDI® Stick:
Responsible marketing, sustainability, and good manufacturing processes—these are the pillars of BIDI Vapor.
“We built our PMTAs based on science, research, and data, and we are confident that the FDA will authorize the BIDI® Stick to stay on the market,” Niraj Patel concluded.
– – – – –
At BIDI Vapor, innovation is key to our mission, with the BIDI® Stick promoting environmental sustainability while providing a unique vaping experience to adult smokers. Contributing to a smoke-free world for our future generations is in BIDI Vapor’s DNA.
Watch the video above to learn more about the BIDI® Story.
Assistance en ligne 24 heures sur 24, 7 jours sur 7, anonymes absolus et livraison rapide. Ainsi, chez un patient prenant du CIALIS quelle que soit la dose 2,5 mg – 20 mg , et chez qui l’administration d’un dérivé nitré est jugée nécessaire pour le pronostic vital, un délai minimum de 48 heures après la dernière prise de CIALIS doit être respecté, avant d’administrer un dérivé nitré Cialis 40 mg, cialis 5mg achat Pilule prix viagra Canada générique inde generique tadalafil achat, 5mg 20mg professionnel sans ordonnance. casino canada Commandez des médicaments bon marché au meilleur prix.